CELLABMED

Cellab Med Co. , Ltd. is a biotechnology company specializing in the development of innovative therapeutic solutions, focusing particularly on CAR-T cell therapy and antibody therapeutics for cancer treatment. Founded in 2019 and headquartered in Seoul, South Korea, Cellab Med Co.

, Ltd. develops advanced cancer therapies. The firm raised KRW 23. 3 billion in a Series B funding round on November 15, 2021, with participation from various investors including AION Asset Management and Wooshin Venture Capital.

CEO Seong-won Song leads the company, which has engaged in two investment deals to date, with no known pivots or subsidiary operations reported. Cellab Med Co. , Ltd. specializes in the development of innovative therapeutic solutions, primarily focusing on CAR-T cell therapy and antibody therapeutics.

Their CAR-T cell therapy products are designed to treat rare and difficult-to-manage cancers, providing hope and treatment options for patients who previously had limited alternatives. Additionally, the company is committed to developing therapeutic antibodies that are effective across a range of diseases while minimizing side effects, thus addressing significant unmet medical needs in the healthcare market. These products are primarily targeted at oncologists, hospitals, and specialized clinics across international markets, with a particular emphasis on regions where advanced cancer treatments are needed most. The company’s integrated R&D approach spans from basic research through to clinical development and manufacturing, showcasing a comprehensive commitment to bringing innovative therapies from the lab to the patient.

Cellab Med Co. , Ltd. generates revenue through direct partnerships with healthcare providers and institutions, focusing on the commercialization of its flagship products, including its CAR-T therapies and therapeutic antibodies. The firm operates a business-to-business model, supplying advanced therapeutic solutions to hospitals and specialized cancer treatment centers, which integrate these innovative products into their treatment regimens.

Pricing structures for these therapeutic offerings are built around the complexity and specialization of the treatments, typically involving case-by-case agreements based on patient needs and clinical use. Through these structured transactions, Cellab Med aims to ensure that its cutting-edge solutions are accessible to healthcare professionals, thereby enhancing patient outcomes in the oncology sector. Following the most recent funding deal on November 15, 2021, in which Cellab Med raised KRW 23. 3 billion in Series B funding, the company plans to enhance its pipeline drug for pancreatic cancer, currently in phase 2 clinical trials for metastatic colorectal cancer.

The investment will support ongoing product improvements and potentially lead to the launch of new therapeutic offerings. Cellab Med also has plans to expand its market presence in regions that require advanced cancer treatments, as it seeks to reach more oncologists and specialized clinics globally.